In the pre-antiretroviral therapy (ART) era, HIV
infection in perinatally infected children was described to follow three
distinct courses. An in utero infection coincident with
immunological cell expansion in the fetus can lead to rapid spread of
virus and culminates in a rapid disease course, with onset of
AIDS and symptoms during the first few months of life and a median
survival time of 6-9 months, if untreated. The majority of perinatally
infected newborns (60-80%) in developed countries present with a much
slower progression of disease, with a median survival time of 6 years
representing the 2nd pattern of disease. The 3rd pattern of disease
occurs in a small percentage (<5%) of perinatally infected children
referred to as long-term non-progressors (LTNPs), who have minimal or no
progression of disease with relatively normal CD4 counts and very low
viral loads for longer than 8 years [1,2].
This variation in susceptibility to HIV-1 infection
and its rate of progression is partly explained by host genetic factors.
Supporting a role for genetic factors in the host, several studies have
shown that susceptibility to HIV-1 in vitro largely varies among
cells from genetically distinct individuals. Conversely, primary cells
from homozygotic twins display much less variation in their
susceptibility to infection. In order to complete a replicative cycle,
HIV-1 must use the cellular machinery at multiple steps and rely on host
cellular proteins. Only a fraction of these host proteins have been
identified, but their role in the HIV-1 susceptibility and progression
is currently a subject of intense investigation [3]. The study by
Palchaudhuri, et al. [4] in the current issue is the first such
study on perinatally infected Indian children linking specific genetic
markers with HIV progression. Approaches used to study these host
genetic factors in vivo have predominantly used LTNPs. Studies on
perinatally infected children in a French cohort have demonstrated this
population to be 2% of the infected population [5]. Prevalence studies
have not been done in India [6].
The host genetic factors involved in HIV infection
and progression can be grouped into those that modulate viral entry,
those that modulate post entry viral replication, and those that
modulate the innate immune response against HIV-1 infection [7]. Among
factors modulating viral entry, HIV-1 co-receptor CCR5 and CXCR4
polymorphisms are being investigated. High level of wild type CCR5
expression on CD4-positive primary T cells is associated with high viral
loads and accelerated disease progression. Studies have characterized
the CCR5Ä32 allele, which has been unequivocally associated with
protection to HIV-1 infection in homozygotic individuals. CCR5Ä32
expresses a truncated co-receptor that is not transported to the cell
surface and thus is incompetent for viral entry [7]. Individuals
homozygous for the Ä32 allele seem to have a normal life expectancy.
Though the CCR5Ä32 allele occurs at a frequency of 4-15% in the
Caucasian population, it is rarely found in Asians and Africans [8].
Recently, CCR5 promoter polymorphisms like CCR5 5902G have been
described to affect HIV progression [9,10]. This allele has been
described to have a high prevalence among LNTPs in the present study.
The beta-chemokines MIP-1á(CCL3), MIP-1â(CCL4), and
RANTES (CCL5) are the natural ligands of CCR5, which after binding to
it, induce its internalization. Thus, high levels of these chemokines
are postulated to provide the host immunity against viral replication
[11]. SDF-1 (also known as CXCL12) is the only known ligand of CXCR4,
which also induces internalization of the receptor [12]. A polymorphism
in the noncoding region of SDF-1 has been reported (SDF1-3’A). In the
homozygous form, the presence of an A at position 801 has been
associated with slower progression to AIDS, as compared to heterozygous
or wild-type homozygous. A number of reports have failed to confirm this
association in other cohorts [13]. Thus, it is not clear whether the
SDF1-3’A variant plays a role in disease progression. In the present
study by Palchaudhuri, et al., only a prevalence of the allele
has been described in the LTNP population, which has not been compared
with controls.
Factors that modulate the innate immune response
include the MHC genes, which are the targets of active research.
Associations have been reported between faster HIV-1 disease progression
and HLA types: A23, A24, A26, B21, B38. Conversely, some studies have
shown associations between delayed AIDS progression and DR4, DR7, B17,
B27, B51, and B57. The exact role of HLA haplotypes in AIDS progression
remains elusive. One possible mechanism is the variable ability of
different HLA molecules in presenting the HIV-1 antigen and inducing a
strong immune response [14]. In the study by Palchaudhuri, et al.
[4], HLA-B*57 polymorphic allele was found in one Slow progressor (SP)
and in one LTNP, while HLA- B*27 was found in one LTNP. Mannose binding
lecithin (MBL) deficiency has also been associated with increased HIV-1
vertical transmission [15].
Intracellular antiviral host factors such as APOBEC3G
(Apolipoprotein B mRNA Editing Catalytic Polypeptide 3G) formerly known
as CEM15, is an endogenous inhibitor of intracellular HIV-1 replication.
An APOBEC3G variant containing a non-synonymous substitution of Arg for
His at amino acid position 186 is present in African-Americans and is
strongly associated with more rapid decline of CD4
1. Dollfus C, Le Chenadec J, Faye A, Blanche S,
Briand N, Rouzioux C, et al. Long-term outcomes in adolescents
perinatally infected with HIV-1 and followed up since birth in the
French perinatal cohort (EPF/ANRS CO10). Clin Infect Dis.
2010;51:214-24.
2. Shah I, Nadiger M. Long term non progressors
(LTNP) with vertically infected HIV children - A report from western
India. Indian J Med Res. 2013;137:210-2.
3. Lama J, Planelles V. Host factors influencing
susceptibility to HIV infection and AIDS progression.
Retrovirology. 2007;4:52.
4. Palchaudhuri R, Neogi, Rao SD, Shet A. Genetic
factors associated with slow progression of HIV among perinatally-infected
Indian children. Indian Pediatr. 2014;51:801-3.
5. Warszawski J, Lechenadec J, Faye A, Dollfus C,
Firtion G, Meyer L, et al. Long-term nonprogression of HIV
infection in children: Evaluation of the ANRS prospective French
pediatric cohort. Clin Infect Dis. 2007;45:785-94.
6. Radhakrishna M, Durga K, Rao RK, Reddy DM, Kondapi
AK. Factors associated with conversion of long-term non-progressors to
progressors: A prospective study of HIV perinatally infected paediatric
survivors. Indian J Med Res. 2013;138:322-8.
7. Lederman MM, Penn-Nicholson A, Cho M, Mosier D.
Biology of CCR5 and its role in HIV infection and treatment. JAMA.
2006;296:815-26.
8. Capoulade-Metay C, Trong LX, Dudoit Y, Versmisse
P, Nguyen NV, Nguyen M, et al. New CCR5 variants associated with
reduced HIV coreceptor function in southeast Asia. AIDS.
2004;18:2243-52.
9. Rathore A, Chatterjee A, Sivarama P, Yamamoto N, Singhal
PK, Dhole TN. Association of CCR5-59029 A/G and CCL3L1 copy number
polymorphism with HIV type 1 transmission/progression among HIV type
1-seropositive and repeatedly sexually exposed HIV type 1-seronegative
North Indians. AIDS Res Hum Retroviruses. 2009;25:1149-56.
10. McDermott DH, Zimmerman PA, Guignard F,
Kleeberger CA, Leitman SF, Murphy PM. CCR5 promoter polymorphism and
HIV-1 disease progression. Lancet. 1998;352;866-70.
11. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK,
Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta
as the major HIV-suppressive factors produced by CD8+ T cells. Science.
1995;270:1811-5.
12. Hendel H, Henon N, Lebuanec H, Lachgar A,
Poncelet H, Caillat-Zucman S, et al. Effects of CCR5, CCR2, and
SDF1 genetic polymorphisms in AIDS progression. J Acquir Immune Defic
Syndr Hum Retrovirol. 1998;19:381-8.
13. Ioannidis JP, Rosenberg PS, Goedert JJ, Ashton
LJ, Benfield TL, Buchbinder SP, et al. Effects of CCR5-Delta32,
CCR2-64I, and SDF-1 3’A alleles on HIV-1 disease progression: An
international metaanalysis of individual-patient data. Ann Intern Med.
2001;135:782-95.
14. Roger M. Influence of host genes on HIV-1 disease
progression. FASEB J. 1998;12:625-8.
15. Boniotto M, Crovella S, Pirulli D, Scarlatti G,
Spano A, Vatta L, et al. Polymorphisms in the MBL2 promoter
correlated with risk of HIV-1 vertical transmission and AIDS
progression. Genes Immun. 2000;1:346–8.
16. Sheehy AM, Gaddis NC, Malim MH. The
antiretroviral enzyme APOBEC3G is degraded by the proteasome in response
to HIV-1 Vif. Nat Med. 2003;9:1404-7.